Vivo Capital related stories
All articles and analysis
VC-backed Instil Bio raises $320m for IPOInstil Bio, a clinical-stage biopharmaceutical company, has raised $320 million for its IPO after pricing its 16 million shares at $20 per share.
Ventyx Biosciences fetches $114mVentyx Biosciences, a biotech company, has raised $114 million in funding.
BlossomHill Therapeutics rallies $71m Series ABlossomHill Therapeutics Inc, a biopharmaceutical company focusing on oncology and autoimmune disorders, has raised $71 million in Series A financing.
ASLAN Pharmaceuticals to raise about $18m in a private placementSingapore-based ASLAN Pharmaceuticals, a drug developer, has agreed to raise about $18 million in a private placement.
- VC-backed Bolt Biotherapeutics debuts IPO
Bolt Biotherapeutics Inc has gone public after pricing its 11.5 million shares at $20 per share.
- Boston Scientific to buy Preventice Solutions
Boston Scientific has agreed to acquire Preventice Solutions, a provider of mobile cardiac health solutions and services.
Vivo Capital appoints three to managing partner and promotes two to partnerVivo Capital has named Dr. Hongbo Lu, Jack Bech Nielsen and Michael Chang to managing partners.
Less pain more gain: venBio and other VCs make great returns on migraine drugsBiotech VCs have played a crucial role in developing medicines for the disorder before selling them to big pharma, and they've realized exceptional returns while making a difference in patients' lives.
- VC-backed Aligos Therapeutics goes public
Aligos Therapeutics, a biopharmaceutical company focused on treating viral infections and liver diseases, has raised about $150 million for its IPO after pricing its 10 million shares at $15 per share.
- VC-backed Metacrine goes public
San Diego-based Metacrine, a developer of therapies for patients with liver, gastrointestinal and metabolic diseases, has raised about $85 million for its IPO after pricing its 6.54 million shares at $13 per share.